Entera Bio Ltd. (ENTX)
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered large molecule therapeutics. Their lead product candidates, EB612 and EB613, target hypoparathyroidism, osteoporosis, and non-union fractures.
Company Overview
Entera Bio Ltd. pioneers oral delivery of large molecule therapeutics, addressing unmet needs in hypoparathyroidism and osteoporosis with Phase II clinical trials underway. With a market cap of $0.05B and a strategic collaboration with Amgen, Entera Bio offers a unique investment opportunity in the biotech sector.
Investment Thesis
Entera Bio presents a compelling investment opportunity due to its innovative oral delivery technology for large molecule therapeutics, addressing a critical need for patient-friendly alternatives to injectable biologics. The company's lead asset, EB612, targeting hypoparathyroidism, is in Phase II trials, offering significant upside potential upon positive results. EB613, with completed Phase II trials for osteoporosis, further validates the platform. The collaboration with Amgen provides external validation and potential for future partnerships. While the company's negative profit margin of -8694.4% reflects its clinical-stage nature, successful clinical trials and potential commercialization could drive substantial revenue growth. The $0.05B market cap suggests significant room for appreciation if the technology proves successful. Key value drivers include positive clinical trial data, strategic partnerships, and eventual FDA approval and commercialization of its lead product candidates. Investing in Entera Bio is a bet on the successful disruption of biologics delivery.
Key Highlights
- EB612 is in Phase II clinical trials for the treatment of hypoparathyroidism, targeting a significant unmet medical need.
- EB613 has completed Phase II clinical trials for the treatment of osteoporosis, demonstrating potential for oral delivery of bone-building therapeutics.
- The company has a research collaboration and license agreement with Amgen Inc., validating its technology and providing potential for future revenue streams.
- Entera Bio's market capitalization is $0.05B, indicating potential for significant growth upon successful clinical development and commercialization.
- The company's negative profit margin of -8694.4% reflects its clinical-stage status, with future profitability dependent on successful product development and market entry.
Competitors
Strengths
- Innovative oral delivery technology for large molecules.
- Lead product candidates in Phase II clinical trials.
- Collaboration with Amgen Inc.
- Focus on unmet medical needs.
Weaknesses
- Clinical-stage company with no currently approved products.
- Negative profit margin and limited financial resources.
- High risk of clinical trial failure.
- Small number of employees.
Catalysts
- Upcoming: Phase II clinical trial results for EB612 in hypoparathyroidism.
- Upcoming: Initiation of Phase II clinical trials for EB613 in additional indications.
- Ongoing: Progress in research collaboration with Amgen Inc.
- Ongoing: Potential for new strategic partnerships and licensing agreements.
Risks
- Potential: Failure to achieve positive results in clinical trials.
- Potential: Regulatory delays or rejection of product candidates.
- Ongoing: Competition from other pharmaceutical companies.
- Ongoing: Dependence on third-party manufacturers and suppliers.
- Potential: Need for additional financing to fund operations.
Growth Opportunities
- Expansion into Additional Indications: Entera Bio can leverage its oral delivery platform to target additional indications beyond hypoparathyroidism and osteoporosis. The market for oral biologics is vast, encompassing a wide range of therapeutic areas, including diabetes, inflammatory diseases, and cancer. By expanding its pipeline, Entera Bio can diversify its revenue streams and reduce its reliance on its lead product candidates. This expansion could begin within the next 3-5 years, following successful clinical trials of EB612 and EB613.
- Strategic Partnerships and Licensing Agreements: Entera Bio can pursue additional strategic partnerships and licensing agreements with pharmaceutical companies to accelerate the development and commercialization of its oral delivery platform. These partnerships can provide valuable funding, expertise, and access to new markets. The collaboration with Amgen serves as a model for future partnerships, which could be initiated within the next 1-2 years.
- Development of Next-Generation Oral Delivery Technologies: Entera Bio can invest in the development of next-generation oral delivery technologies to further improve the bioavailability and efficacy of its products. This could involve exploring new formulation strategies, drug delivery devices, and targeting mechanisms. These advancements could lead to more potent and convenient oral biologics, enhancing Entera Bio's competitive advantage. R&D in this area is ongoing.
- Geographic Expansion: Entera Bio can expand its geographic reach beyond Israel and the United States to tap into new markets for its products. This could involve establishing partnerships with local distributors or setting up its own sales and marketing operations in key regions, such as Europe and Asia. This expansion could be initiated within the next 3-5 years, following regulatory approval of its lead product candidates in major markets.
- Acquisition of Complementary Technologies or Companies: Entera Bio could consider acquiring complementary technologies or companies to expand its capabilities and accelerate its growth. This could involve acquiring companies with expertise in formulation development, drug delivery, or clinical trial management. Such acquisitions could strengthen Entera Bio's competitive position and provide access to new technologies and markets. This is a potential long-term growth strategy.
Opportunities
- Expansion into additional indications.
- Strategic partnerships and licensing agreements.
- Development of next-generation oral delivery technologies.
- Geographic expansion.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and lengthy approval processes.
- Potential for product liability claims.
- Changes in healthcare reimbursement policies.
Competitive Advantages
- Proprietary oral delivery technology for large molecules.
- Patent protection for its product candidates and delivery platform.
- Clinical trial data demonstrating the safety and efficacy of its products.
- Strategic partnerships with established pharmaceutical companies.
About
Entera Bio Ltd., founded in 2009 and based in Jerusalem, Israel, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing orally delivered large molecule therapeutics. Recognizing the limitations of traditional injectable biologics, Entera Bio is focused on creating patient-friendly oral formulations for conditions with significant unmet medical needs. The company's lead product candidate, EB612, is currently in Phase II clinical trials for the treatment of hypoparathyroidism, a rare endocrine disorder characterized by insufficient parathyroid hormone production. Another key asset, EB613, has completed Phase II clinical trials for osteoporosis and is in Phase I trials for non-union fractures, showcasing the platform's versatility. Entera Bio's technology aims to improve drug bioavailability and patient compliance through oral administration. The company also has a research collaboration and license agreement with Amgen Inc., focused on the discovery and development of clinical candidates in inflammatory disease and other serious illnesses, highlighting the potential of Entera Bio's oral delivery platform to address a wide range of therapeutic areas. With a small team of 18 employees, Entera Bio operates with a lean structure, prioritizing efficient clinical development and strategic partnerships.
What They Do
- Develop orally delivered large molecule therapeutics.
- Focus on unmet medical needs in endocrinology and bone diseases.
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
- Seek regulatory approval from agencies like the FDA.
- Collaborate with pharmaceutical companies for research and development.
- Aim to commercialize their products and generate revenue.
Business Model
- Develop and out-license or sell orally delivered therapeutics.
- Generate revenue through research collaborations and licensing agreements.
- Potentially generate revenue through direct sales of approved products.
- Focus on developing innovative therapies with high market potential.
Industry Context
Entera Bio operates in the competitive biotechnology industry, which is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The market for oral biologics delivery is growing, driven by the desire for more convenient and patient-friendly alternatives to injectable drugs. Entera Bio's competitors include companies developing alternative delivery methods for biologics and those developing competing therapies for hypoparathyroidism and osteoporosis. The company's success depends on its ability to demonstrate the safety and efficacy of its oral delivery platform and secure regulatory approval for its product candidates. Competitors like ABOS, AGEN, ANIX, HURA, and INO are also vying for market share in the broader biotechnology landscape.
Key Customers
- Patients suffering from hypoparathyroidism.
- Patients suffering from osteoporosis.
- Pharmaceutical companies seeking novel drug delivery technologies.
- Healthcare providers prescribing treatments for bone and endocrine disorders.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $82,000 | -$2M | $0.00 |
| Q3 2024 | $42,000 | -$3M | $0.00 |
| Q2 2024 | $57,000 | -$2M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Entera Bio Ltd. (ENTX) stock price: $1.77 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in Entera Bio's pipeline, which may indicate strong future growth.
- •Community sentiment has shifted positively as discussions around their innovative drug delivery system gained traction.
- •Analysts are intrigued by the potential market for their lead product, which could address unmet medical needs and capture significant attention.
- •Recent partnerships or collaborations have enhanced the company's visibility and credibility within the biotech sector.
Why Bear
- •Concerns remain about the competitive landscape, with several established players also targeting similar therapeutic areas.
- •Social sentiment has shown volatility, with some investors expressing skepticism about the company's ability to execute its strategy effectively.
- •The lack of recent positive clinical trial results may dampen enthusiasm and lead to increased caution among investors.
- •Market perception is mixed, as some view Entera Bio's valuation as stretched given the current stage of its product development.
Latest News
-
Daily – Vickers Top Insider Picks for 02/19/2026
Argus Research · Feb 19, 2026
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Feb 9, 2026
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Sep 28, 2022
-
58 Biggest Movers From Friday
· Jun 21, 2021
Technical Analysis
Rationale
AI-generated technical analysis for ENTX including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Entera Bio Ltd. (ENTX) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for ENTX.
Make a Prediction
Set your price target for Entera Bio Ltd. (ENTX), choose a timeframe, and track your prediction accuracy.
Current price: $1.77
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENTX.
Price Targets
Wall Street price target analysis for ENTX.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 5/100
Gross margin data is currently unavailable for this company.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates ENTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Entera Bio Ltd. do?
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing orally delivered large molecule therapeutics. Their proprietary technology aims to replace injectable biologics with patient-friendly oral formulations. The company's lead product candidates, EB612 and EB613, target hypoparathyroidism and osteoporosis, respectively. Entera Bio's business model involves developing and out-licensing or selling its oral therapeutics, generating revenue through research collaborations, licensing agreements, and potential direct sales of approved products. The company is focused on developing innovative therapies with high market potential.
Is ENTX stock a good buy?
ENTX stock is a speculative investment suitable for investors with a high-risk tolerance. The company's potential lies in its innovative oral delivery technology and the successful development of its lead product candidates. Positive results from ongoing clinical trials, particularly for EB612, could significantly increase the stock's value. However, the company's negative profit margin and limited financial resources pose significant risks. Investors should carefully consider the potential upside and downside before investing in ENTX, recognizing that it is a clinical-stage company with no guarantee of future success.
What are the main risks for ENTX?
The main risks for ENTX include the potential failure of its lead product candidates in clinical trials, which would significantly impact the company's value. Regulatory hurdles and delays in obtaining FDA approval also pose a risk. Competition from established pharmaceutical companies with greater resources and approved products is another significant challenge. Additionally, ENTX relies on third-party manufacturers and suppliers, which could disrupt its supply chain. The company's need for additional financing to fund operations could also dilute existing shareholders' equity.
Is ENTX a good stock to buy?
Whether ENTX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the ENTX MoonshotScore?
The MoonshotScore for ENTX is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is ENTX data updated?
ENTX stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to ENTX is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for ENTX?
Growth catalysts for Entera Bio Ltd. (ENTX) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Entera Bio Ltd.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are ENTX's main competitors?
Entera Bio Ltd. (ENTX) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether ENTX has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about ENTX?
Wall Street analyst coverage for ENTX includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is ENTX's market cap?
Market capitalization (market cap) for ENTX is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows ENTX's current market cap alongside enterprise value and other valuation metrics.
How has ENTX stock performed recently?
ENTX's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing ENTX's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in ENTX?
Key risk categories for ENTX include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures ENTX's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling ENTX?
Insider trading activity for ENTX tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is ENTX a good stock for beginners?
Entera Bio Ltd. (ENTX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is ENTX for first-time investors?
Every stock carries risk, including Entera Bio Ltd. (ENTX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like ENTX.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on limited publicly available data. Clinical trial outcomes are inherently uncertain.